Merck Sees Upside in Pipeline, Raises Revenue Confidence

At the Morgan Stanley Global Healthcare Conference, Merck outlined its pipeline and commercial strategy, which management said is gaining momentum across launches, clinical data, and business development. Chairman and Chief Executive Rob Davis described the company as 'hitting on all cylinders,' while also noting that it's working through a changing market for drug access, reimbursement, and cross-border innovation.

The company has increased confidence in its $70 billion mid-2030s pipeline revenue goal and may raise it soon. Key highlights include positive data for the INT personalized neoantigen therapy, sacituzumab tirumotecan, and tulisokibart. Merck also discussed enlicitide, its newly approved oral PCSK9 inhibitor, which has already received positive cardiovascular outcomes label language.

The company sees several sources of upside in its pipeline, including the INT program with Moderna, which is moving faster than expected after positive Phase III interim data in melanoma. Sacituzumab tirumotecan delivered a positive readout earlier than Merck had expected, de-risking the program.

Enlicitide can reduce LDL cholesterol by up to 60% and management aims for low pricing to broaden access and increase use. The target population is about 30 million U.S. patients on lipid-lowering therapy who are not at goal. Davis said his goal is to move PCSK9 use from about 5% of eligible patients to 50% or more.

Merck's strong pipeline execution is supported by solid fundamentals, with revenue of $66.6 billion and an impressive gross profit margin of 75.9% in the last twelve months. The company has raised its dividend for 15 consecutive years and maintains a current yield of 2.36%, demonstrating financial stability alongside growth investments.